

## Welcome to DialogClassic Web(tm)

Dialog level 04.20.00D

Last logoff: 21dec04 11:01:55

Logon file001 27dec04 13:37:57

\*\*\* ANNOUNCEMENT \*\*\*

\*\*\*

--Important Notice to Freelance Authors--

See HELP FREELANCE for more information

\*\*\*

NEW FILES RELEASED

\*\*\*German Patents Fulltext (File 324)

\*\*\*Beilstein Abstracts (File 393)

\*\*\*Beilstein Facts (File 390)

\*\*\*Beilstein Reactions (File 391)

\*\*\*F-D-C Gold/Silver Sheet (File 184)

\*\*\*

UPDATING RESUMED

\*\*\*

RELOADED

\*\*\*Toxfile (File 156)

REMOVED

\*\*\*Textile Technology Digest (File 119)

\*\*\*

>>> Enter BEGIN HOMEBASE for Dialog Announcements <<<  
>>> of new databases, price changes, etc. <<<

\*\*\*\*

KWIC is set to 50.

HIGHLIGHT set on as ' '

\* \* \*

File 1:ERIC 1966-2004/Jul 21

(c) format only 2004 The Dialog Corporation

Set Items Description

--- -----

Cost is in DialUnits

?

B 155, 5, 73

27dec04 13:38:22 User259876 Session D698.1

\$0.79 0.227 DialUnits File1

\$0.79 Estimated cost File1

\$0.09 INTERNET

\$0.88 Estimated cost this search

\$0.88 Estimated total session cost 0.227 DialUnits

SYSTEM:OS - DIALOG OneSearch

File 155:MEDLINE(R) 1951-2004/Dec W1

(c) format only 2004 The Dialog Corp.

**\*File 155: Medline has stopped updating as of December 7, 2004.**

Please see HELP NEWS 155 for details.

File 5:Biosis Previews(R) 1969-2004/Dec W2

(c) 2004 BIOSIS

File 73:EMBASE 1974-2004/Dec W2

(c) 2004 Elsevier Science B.V.

Set Items Description

--- -----

?

S (OCULAR (W) GENE (W) THERAPY)

180310 OCULAR

2373325 GENE

5320901 THERAPY

S1 43 (OCULAR (W) GENE (W) THERAPY)

?  
 S S1 AND (OCULAR (W) WOUND)  
     43 S1  
     180310 OCULAR  
     209480 WOUND  
     88 OCULAR (W) WOUND  
   S2 0 S1 AND (OCULAR (W) WOUND)  
 ?  
 S S1 AND (CORNEAL (W) EPITHELIAL (W) WOUND)  
     43 S1  
     103753 CORNEAL  
     425747 EPITHELIAL  
     209480 WOUND  
     646 CORNEAL (W) EPITHELIAL (W) WOUND  
   S3 0 S1 AND (CORNEAL (W) EPITHELIAL (W) WOUND)  
 ?  
 S S1 AND (CORNEAL (W) ULCERATION)  
     43 S1  
     103753 CORNEAL  
     39467 ULCERATION  
     1460 CORNEAL (W) ULCERATION  
   S4 0 S1 AND (CORNEAL (W) ULCERATION)  
 ?

Set	Items	Description
S1	43	(OCULAR (W) GENE (W) THERAPY)
S2	0	S1 AND (OCULAR (W) WOUND)
S3	0	S1 AND (CORNEAL (W) EPITHELIAL (W) WOUND)
S4	0	S1 AND (CORNEAL (W) ULCERATION)

?  
 S S1 AND (TGF-BETA)  
     43 S1  
     378 TGF-BETA  
   S5 0 S1 AND (TGF-BETA)  
 ?

RD S1  
 ...completed examining records  
   S6 24 RD S1 (unique items)  
 ?

S S6 NOT PY>1994  
     24 S6  
     14475568 PY>1994  
   S7 1 S6 NOT PY>1994  
 ?

T S7/3,K/ALL

7/3,K/1 (Item 1 from file: 155)  
 DIALOG(R) File 155:MEDLINE(R)  
 (c) format only 2004 The Dialog Corp. All rts. reserv.

09892813 PMID: 8240099  
 Ocular gene therapy□. From fantasy to foreseeable reality.□  
 Zack D J  
 Archives of ophthalmology (UNITED STATES) Nov 1993, 111 (11) p1477-9  
 , ISSN 0003-9950 Journal Code: 7706534  
 Document type: Editorial  
 Languages: ENGLISH  
 Main Citation Owner: NLM  
 Record type: Completed

Ocular gene therapy□. From fantasy to foreseeable reality.□  
 ?

Set	Items	Description
S1	43	(OCULAR (W) GENE (W) THERAPY)

S2 0 S1 AND (OCULAR (W) WOUND)  
 S3 0 S1 AND (CORNEAL (W) EPITHELIAL (W) WOUND)  
 S4 0 S1 AND (CORNEAL (W) ULCERATION)  
 S5 0 S1 AND (TGF-BETA)  
 S6 24 RD S1 (unique items)  
 S7 1 S6 NOT PY>1994

?

S S6 NOT S7

24 S6

1 S7

S8 23 S6 NOT S7

?

T S8/3,K/ALL

8/3,K/1 (Item 1 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

14338817 PMID: 10331808

**Reduction of fibronectin expression by intravitreal administration of antisense oligonucleotides.**

Roy S; Zhang K; Roth T; Vinogradov S; Kao R S; Kabanov A

Schepens Eye Research Institute, Harvard Medical School, Boston, MA 02114, USA. sayon@vision.eri.harvard.edu

Nature biotechnology (UNITED STATES) May 1999, 17 (5) p476-9, ISSN 1087-0156 Journal Code: 9604648

Contract/Grant No.: EY11990-01A1; EY; NEI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... the carrier was detected histologically. Thus, intravitreal delivery of antisense oligonucleotides to modulate abnormal gene expression in retinal diseases may be an effective approach for ocular gene therapy

8/3,K/2 (Item 2 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13631312 PMID: 9323715

**Ocular gene therapy : experimental studies and clinical possibilities.**

Murata T; Kimura H; Sakamoto T; Osusky R; Spee C; Stout T J; Hinton D R; Ryan S J

Doheny Eye Institute, Los Angeles, CA 90033, USA.

Ophthalmic research (SWITZERLAND) 1997, 29 (5) p242-51, ISSN 0030-3747 Journal Code: 0267442

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Ocular gene therapy : experimental studies and clinical possibilities.**

... hereditary ocular diseases, including retinitis pigmentosa, tumors such as retinoblastoma or melanoma, and acquired proliferative and neovascular retinal disorders. We have demonstrated the feasibility of ocular gene therapy in a rabbit model of proliferative vitreoretinopathy, using retroviral vectors containing the herpes simplex virus thymidine kinase 'suicide' gene. Although in vivo transduction efficiency is...

8/3,K/3 (Item 3 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

13581911 PMID: 9267594

Ocular gene therapy : the basic science and current state of research.

da Cruz L; Rakoczy P; Constable I

Lions Eye Institute, Nedlands, Australia. lyndondc@cyllene.uwa.edu.au

Australian and New Zealand journal of ophthalmology (AUSTRALIA) May 1997, 25 (2) p97-104, ISSN 0814-9763 Journal Code: 8505423

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Ocular gene therapy : the basic science and current state of research.

8/3,K/4 (Item 4 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12472580 PMID: 12907168

Characterization of adenovirus p21 gene transfer, biodistribution, and immune response after local ocular delivery in New Zealand white rabbits.

Wen S F; Chen Z; Nery J; Faha B

Canji Inc., 3525 John Hopkins Court, San Diego, CA 92121, USA.

Experimental eye research (England) Sep 2003, 77 (3) p355-65, ISSN 0014-4835 Journal Code: 0370707

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

...subsequent administration to the contralateral eye in the same animal. These results show that local delivery to conjunctiva may be a suitable delivery mode for ocular gene therapy .

8/3,K/5 (Item 5 from file: 155)

DIALOG(R) File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12427500 PMID: 12833125

Simian immunodeficiency virus-based lentivirus vector for retinal gene transfer: a preclinical safety study in adult rats.

Ikeda Y; Goto Y; Yonemitsu Y; Miyazaki M; Sakamoto T; Ishibashi T; Tabata T; Ueda Y; Hasegawa M; Tobimatsu S; Sueishi K

Division of Pathophysiological and Experimental Pathology, Department of Pathology, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan.

Gene therapy (England) Jul 2003, 10 (14) p1161-9, ISSN 0969-7128 Journal Code: 9421525

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Although lentivirus vectors hold promise for ocular gene therapy , they also have potential safety issues, particularly in the case of the current human immunodeficiency virus-based vectors. We recently developed a novel lentivirus vector...

8/3,K/6 (Item 6 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

12366579 PMID: 12742346

**Recent developments in ocular gene therapy.**

Borras Teresa

Department of Ophthalmology, University of North Carolina School of Medicine, 6109 Neuroscience Research Building, Campus Box 7041, 103 Mason Farm Road, Chapel Hill, NC 27599, USA. tborras@med.unc.edu

Experimental eye research (England) Jun 2003, 76 (6) p643-52, ISSN 0014-4835 Journal Code: 0370707

Contract/Grant No.: EY 11906; EY; NEI; EY13126; EY; NEI

Document type: Journal Article; Review; Review, Academic

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

**Recent developments in ocular gene therapy.**

...to move from the use of reporters, to genes with potential therapeutic value. In this paper, rather than giving an overview from the beginning of **ocular gene therapy**, I have chosen to review its most recent advances. Although numerous issues remain to be solved, the emerging picture is encouraging. Within the experimental setting...

8/3,K/7 (Item 7 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11953496 PMID: 12162813

**Sustained transduction of ocular cells with a bovine immunodeficiency viral vector.**

Takahashi Kyoichi; Luo Tianci; Saishin Yoshitsugu; Saishin Yumiko; Sung Jennifer; Hackett Sean; Brazzell R K; Kaleko Michael; Campochiaro Peter A  
Department of Ophthalmology, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.

Human gene therapy (United States) Jul 20 2002, 13 (11) p1305-16, ISSN 1043-0342 Journal Code: 9008950

Contract/Grant No.: EY05951; EY; NEI; EY12609; EY; NEI; P30EY1765; EY; NEI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... a lentivirus that shares many characteristics with HIV, but does not cause human disease. In this study, we investigated the potential of BIV vectors for **ocular gene therapy**. An enhanced green fluorescent protein (eGFP)-encoding reporter gene was packaged in recombinant BIV vector (BIV.eGFP). Adult C57BL/6 mice were given an intravitreal...  
...toxicity in any eyes. These data show that BIV vectors mediate rapid and sustained transduction of RPE cells, suggesting that they may be useful for **ocular gene therapy** targeting RPE cells.

8/3,K/8 (Item 8 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

11660513 PMID: 11829519

**A deviant immune response to viral proteins and transgene product is generated on subretinal administration of adenovirus and adeno-associated**

**virus.**

Anand Vibha; Duffy Bethany; Yang Zaixin; Dejneka Nadine S; Maguire Albert M; Bennett Jean

Univeristy of Pennsylvania, F. M. Kirby Center for Molecular Ophthalmology, 310 Stellar Chance Labs, Scheie Eye Institute, 422 Curie Blvd, Philadelphia, Pennsylvania 19104-6069, USA.

Molecular therapy - the journal of the American Society of Gene Therapy (United States) Feb 2002, 5 (2) p125-32, ISSN 1525-0016

Journal Code: 100890581

Contract/Grant No.: EY10820; EY; NEI; EY12156; EY; NEI

Document type: Journal Article

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

... the retina. This subsequently generates a population of immunosuppressive Th2-type, cytokine-secreting, splenic T cells. This response may be advantageous to the development of ocular gene therapy

8/3,K/9 (Item 9 from file: 155)

DIALOG(R)File 155:MEDLINE(R)

(c) format only 2004 The Dialog Corp. All rts. reserv.

10840693 PMID: 10967033

Ocular gene therapy[]: quo vadis?[]

Hauswirth W W; Beaufriere L

Department of Molecular Genetics and Microbiology, Center for Gene Therapy, University of Florida, Gainesville 32610-0284, USA.  
hauswrth@eye1.eye.ufl.edu

Investigative ophthalmology & visual science (UNITED STATES) Sep 2000,

41 (10) p2821-6, ISSN 0146-0404 Journal Code: 7703701

Document type: Journal Article; Review; Review, Tutorial

Languages: ENGLISH

Main Citation Owner: NLM

Record type: Completed

Ocular gene therapy[]: quo vadis?[]

8/3,K/10 (Item 1 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0014582541 BIOSIS NO.: 200300538731

**PHIC31 INTEGRASE AS A CANDIDATE FOR RETINAL GENE THERAPY**

AUTHOR: Chalberg T W (Reprint); Calos M P (Reprint)

AUTHOR ADDRESS: Genetics, Stanford Sch of Med, Stanford, CA, USA\*\*USA

JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2003 p

Abstract No. 2337 2003 2003

MEDIUM: cd-rom

CONFERENCE/MEETING: Annual Meeting of the Association for Research in Vision and Ophthalmology Fort Lauderdale, FL, USA May 04-08, 2003;  
20030504

SPONSOR: Association for Research in Vision and Ophthalmology

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Abstract

LANGUAGE: English

...ABSTRACT: pseudo attP sites). PhiC31 integrase can mediate recombination between such sites and attB (1). We aim to use the phiC31 integrase as a tool for ocular gene therapy and will first advance the technology in animal models of retinal degeneration. Methods: In order to establish whether phiC31 integrase could be effective for in...

8/3,K/11 (Item 2 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014556487 BIOSIS NO.: 200300511850

**EVALUATION OF MINIMAL EIAV BASED VECTORS FOR INTRAOCULAR GENE TRANSFER**  
AUTHOR: Balaggan K S (Reprint); Bainbridge J W B (Reprint); Tschernutter M (Reprint); Esapa M; Binley K; Naylor S; Ali R R (Reprint)  
AUTHOR ADDRESS: Molecular Genetics, Institute of Ophthalmology, London, UK  
\*\*UK  
JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2003 p Abstract No. 442 2003 2003  
MEDIUM: cd-rom  
CONFERENCE/MEETING: Annual Meeting of the Association for Research in Vision and Ophthalmology Fort Lauderdale, FL, USA May 04-08, 2003; 20030504  
SPONSOR: Association for Research in Vision and Ophthalmology  
DOCUMENT TYPE: Meeting; Meeting Poster; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

...ABSTRACT: of recombination to generate RCL (replication competent lentivirus). The aims of this study were to define the potential role of an EIAV based vector in **ocular gene therapy**. Methods: EIAV vectors carrying a GFP transgene driven by a CMV promoter were pseudotyped with either VSV-G or rabies envelopes. Following intravitreal, anterior chamber...

8/3,K/12 (Item 3 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014250888 BIOSIS NO.: 200300209607

**Polyplex-mediated gene transfer to retinal pigment epithelial cells.**  
AUTHOR: Mannisto M (Reprint); Ronkko S (Reprint); Matto M; Pelkonen J; Urtti A  
AUTHOR ADDRESS: Department of Pharmaceutics, University of Kuopio, 70211, P.O. Box 1627, Kuopio, Finland\*\*Finland  
JOURNAL: Journal of Controlled Release 87 (1-3): p279-280 21 February, 2003 2003  
MEDIUM: print  
CONFERENCE/MEETING: Proceedings of the Seventh European Symposium on Controlled Drug Delivery Noordwijk aan Zee, Netherlands April 03-05, 2002 ; 20020403  
ISSN: 0168-3659 (ISSN print)  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Citation  
LANGUAGE: English

DESCRIPTORS:

...METHODS & EQUIPMENT: **ocular gene therapy** --

8/3,K/13 (Item 4 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014206985 BIOSIS NO.: 200300165704

**Adenoviral Serotype Influences the Efficiency of Adenoviral-Mediated Transgene Delivery for Gene Therapy.**  
AUTHOR: Hurwitz R L (Reprint); Mahoney T; Lin J -R; Hurwitz C (Reprint); Hurwitz M Y (Reprint)

AUTHOR ADDRESS: Pediatric Hematology/Oncology, Baylor College of Medicine,  
Houston, TX, USA\*\*USA  
JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2002 p  
Abstract No. 4621 2002 2002  
MEDIUM: cd-rom  
CONFERENCE/MEETING: Annual Meeting of the Association For Research in  
Vision and Ophthalmology Fort Lauderdale, Florida, USA May 05-10, 2002;  
20020505  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

ABSTRACT: Purpose: To compare the efficiency of adenoviral serotype 5  
vectors to chimeric adenoviral serotype 5 vectors expressing adenoviral  
serotype 35 fibers in transgene expression for **ocular gene therapy**  
Methods: Adenoviral 5 constructs containing a green fluorescent reporter  
gene (AdV5-GFP) were compared to similar constructs using a chimeric  
adenovirus expressing fiber proteins derived...

...of twice the amount of GFP protein than that mediated by the AdV5  
vector. AdV5/F35 may be superior to AdV5 as vector for some **ocular  
gene therapy** applications.

8/3,K/14 (Item 5 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014206978 BIOSIS NO.: 200300165697  
**Long-term Transduction of Retinal Pigmented Epithelial (RPE) Cells With a  
Bovine Immunodeficiency Viral (BIV) Vector.**  
AUTHOR: Sung J U (Reprint); Takahashi K (Reprint); Luo T; Saishin Y  
(Reprint); Kaleko M; Hackett S (Reprint); Campochiaro P (Reprint)  
AUTHOR ADDRESS: Ophthalmology, Johns Hopkins University, Baltimore, MD, USA  
\*\*USA  
JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2002 p  
Abstract No. 4614 2002 2002  
MEDIUM: cd-rom  
CONFERENCE/MEETING: Annual Meeting of the Association For Research in  
Vision and Ophthalmology Fort Lauderdale, Florida, USA May 05-10, 2002;  
20020505  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

...ABSTRACT: a lentivirus that shares many characteristics with HIV, but  
does not cause human disease. In this study, we investigated the  
potential of BIV vector for **ocular gene therapy**. Methods: A green  
fluorescent protein (eGFP) reporter gene was packaged in recombinant BIV  
vector. The BIV.eGFP was grown in 293T cells, concentrated from cell...

...Conclusions: There is rapid onset, long duration transduction of RPE  
cells after subretinal injection of BIV.eGFP, suggesting that BIV vectors  
may be useful for **ocular gene therapy** targeting RPE cells.

8/3,K/15 (Item 6 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014206666 BIOSIS NO.: 200300165385  
**Studies of Motor Activity To Reflect Vision In Rpe65-/- And C57 Mice.**  
AUTHOR: Daniels D M (Reprint)  
AUTHOR ADDRESS: Ctr Ophthal and Vis Sci, University Western Australia,  
Perth, Australia\*\*Australia



JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2002 p  
Abstract No. 3953 2002 2002  
MEDIUM: cd-rom  
CONFERENCE/MEETING: Annual Meeting of the Association For Research in  
Vision and Ophthalmology Fort Lauderdale, Florida, USA May 05-10, 2002;  
20020505  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

...ABSTRACT: compared with the C57. The reliability of this approach  
suggests it's future role as a means of assessing recovery of visual  
function in ongoing ocular gene therapy work.

8/3,K/16 (Item 7 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014196587 BIOSIS NO.: 200300155306  
**Biodistribution of an Adenovirus Encoding Human p21WAF1/Cip-1(rAd-p21)  
Following Subconjunctival Injection in Rabbits.**  
AUTHOR: Chen Z Z (Reprint); Wen S; Maneval D (Reprint); Hess M (Reprint);  
Nery J; Kaufman P; Nickells R; Faha B (Reprint)  
AUTHOR ADDRESS: Pharmacology, Canji Inc, San Diego, CA, USA\*\*USA  
JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2002 p  
Abstract No. 3334 2002 2002  
MEDIUM: cd-rom  
CONFERENCE/MEETING: Annual Meeting of the Association For Research in  
Vision and Ophthalmology Fort Lauderdale, Florida, USA May 05-10, 2002;  
20020505  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

...ABSTRACT: is minimal and rAd-p21 transgene expression is stable in the  
eye. Thus, subconjunctival injection of adenovirus vectors may be a  
suitable delivery mode for ocular gene therapy .

8/3,K/17 (Item 8 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0014196442 BIOSIS NO.: 200300155161  
**Transduction of Primary Rabbit Lacrimal Acini With Replication-Incompetent  
Adenovirus Serotype 5 Inhibits Exocytosis and Transcytosis.**  
AUTHOR: Hamm-Alvarez S F (Reprint); Wang Y (Reprint); Mazurek C; Kasahara N  
AUTHOR ADDRESS: Pharmaceutical Sciences, University of Southern California,  
Los Angeles, CA, USA\*\*USA  
JOURNAL: ARVO Annual Meeting Abstract Search and Program Planner 2002 p  
Abstract No. 3139 2002 2002  
MEDIUM: cd-rom  
CONFERENCE/MEETING: Annual Meeting of the Association For Research in  
Vision and Ophthalmology Fort Lauderdale, Florida, USA May 05-10, 2002;  
20020505  
DOCUMENT TYPE: Meeting; Meeting Abstract  
RECORD TYPE: Abstract  
LANGUAGE: English

...ABSTRACT: elevating basal exocytosis. The loss of apical rab3D-enriched  
secretory vesicles suggests that Ad may alter secretory vesicle  
maturation, thereby uncoupling stimulated and basal exocytosis. Ocular  
gene therapy strategies using Ad-derived materials may therefore alter  
the quantity and composition of tear fluid.

## DESCRIPTORS:

...METHODS &amp; EQUIPMENT: ocular gene therapy --

8/3,K/18 (Item 9 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0013693828 BIOSIS NO.: 200200287339

**Gene transfer to the nonhuman primate retina with recombinant feline immunodeficiency virus vectors**

AUTHOR: Lotery Andrew J (Reprint); Derksen Todd A; Russell Stephen R; Mullins Robert F; Sauter Sybille; Affatigato Louisa M; Stone Edwin M; Davidson Beverly L

AUTHOR ADDRESS: Department of Ophthalmology and Visual Sciences, University of Iowa Hospitals and Clinics, 200 Hawkins Drive, Iowa City, IA, 52242, USA\*\*USA

JOURNAL: Human Gene Therapy 13 (6): p689-696 April 10, 2002 2002

MEDIUM: print

ISSN: 1043-0342

DOCUMENT TYPE: Article

RECORD TYPE: Abstract

LANGUAGE: English

## DESCRIPTORS:

...METHODS &amp; EQUIPMENT: ocular gene therapy --

8/3,K/19 (Item 10 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0013533382 BIOSIS NO.: 200200126893

Ocular gene therapy

AUTHOR: Cuthbertson R A

AUTHOR ADDRESS: San Francisco, Calif., USA\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1215 (4): p4077 Oct. 27, 1998 1998

MEDIUM: print

PATENT NUMBER: US 5827702 PATENT DATE GRANTED: Oct. 27, 1998 19981027

PATENT CLASSIFICATION: 435-172.1 PATENT ASSIGNEE: GENENTECH, INC.

PATENT COUNTRY: USA

ISSN: 0098-1133

DOCUMENT TYPE: Patent

RECORD TYPE: Citation

LANGUAGE: English

Ocular gene therapy

8/3,K/20 (Item 11 from file: 5)

DIALOG(R)File 5:Biosis Previews(R)

(c) 2004 BIOSIS. All rts. reserv.

0013019729 BIOSIS NO.: 200100191568

**Replication competent, avirulent Herpes simplex virus as a vector for neural and ocular gene therapy**

AUTHOR: Brandt Curtis R (Reprint); Kalil Ronald E; Agarwala Seema

AUTHOR ADDRESS: Oregon, WI, USA\*\*USA

JOURNAL: Official Gazette of the United States Patent and Trademark Office Patents 1237 (4): Aug. 22, 2000 2000

MEDIUM: e-file

PATENT NUMBER: US 6106826 PATENT DATE GRANTED: August 22, 2000 20000822

PATENT CLASSIFICATION: 424-932 PATENT ASSIGNEE: Wisconsin Alumni Research Foundation PATENT COUNTRY: USA

ISSN: 0098-1133  
DOCUMENT TYPE: Patent  
RECORD TYPE: Abstract  
LANGUAGE: English

**Replication competent, avirulent Herpes simplex virus as a vector for  
neural and ocular gene therapy**

8/3,K/21 (Item 12 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0012067883 BIOSIS NO.: 199900327543

**Evaluation of CMV promoter-driven transgene expression for ocular gene  
therapy**

AUTHOR: Aguilar H H (Reprint); Gonzales J C (Reprint); Seggern Dvon  
(Reprint); Friedlander M (Reprint); Nemerow G (Reprint); Ghazal P  
(Reprint)

AUTHOR ADDRESS: Program in Ocular Gene Therapy, Scripps Research Institute,  
La Jolla, CA, USA\*\*USA

JOURNAL: IOVS 40 (4): pS575 March 15, 1999 1999

MEDIUM: print

CONFERENCE/MEETING: Annual Meeting of the Association for Research in  
Vision and Ophthalmology Fort Lauderdale, Florida, USA May 9-14, 1999;  
19990509

SPONSOR: Association for Research in Vision and Ophthalmology

DOCUMENT TYPE: Meeting; Meeting Abstract

RECORD TYPE: Citation

LANGUAGE: English

**Evaluation of CMV promoter-driven transgene expression for ocular gene  
therapy**

DESCRIPTORS:

MISCELLANEOUS TERMS: ... ocular gene therapy ;

8/3,K/22 (Item 13 from file: 5)  
DIALOG(R)File 5:Biosis Previews(R)  
(c) 2004 BIOSIS. All rts. reserv.

0011159702 BIOSIS NO.: 199799793762

**Gene therapy for inherited retinal degeneration**

AUTHOR: Ali R R (Reprint); Reichel M B; Hunt D M; Bhattacharya S S

AUTHOR ADDRESS: Dep. Mol. Genet., Inst. Ophthalmol., UCL, Bath St., London  
EC1V, UK\*\*UK

JOURNAL: British Journal of Ophthalmology 81 (9): p795-801 1997 1997

ISSN: 0007-1161

DOCUMENT TYPE: Article

RECORD TYPE: Citation

LANGUAGE: English

DESCRIPTORS:

MISCELLANEOUS TERMS: ... OCULAR GENE THERAPY ;

8/3,K/23 (Item 1 from file: 73)  
DIALOG(R)File 73:EMBASE  
(c) 2004 Elsevier Science B.V. All rts. reserv.

12318121 EMBASE No: 2003429804

**Clinical potentials of ocular gene therapy**

Li L.

L. Li, People's Hosp. Guangxi Zhuang A. R., Nanning 530021 China

AUTHOR EMAIL: lily21cn@yahoo.com.cn

Chinese Ophthalmic Research ( CHIN. OPHTHALMIC RES. ) (China) 2003,  
 21/5 (546-549)  
 CODEN: YAYAF ISSN: 1003-0808  
 DOCUMENT TYPE: Journal ; Review  
 LANGUAGE: CHINESE SUMMARY LANGUAGE: ENGLISH; CHINESE  
 NUMBER OF REFERENCES: 25

### Clinical potentials of ocular gene therapy

?

Set	Items	Description
S1	43	(OCULAR (W) GENE (W) THERAPY)
S2	0	S1 AND (OCULAR (W) WOUND)
S3	0	S1 AND (CORNEAL (W) EPITHELIAL (W) WOUND)
S4	0	S1 AND (CORNEAL (W) ULCERATION)
S5	0	S1 AND (TGF-BETA)
S6	24	RD S1 (unique items)
S7	1	S6 NOT PY>1994
S8	23	S6 NOT S7

?

### COST

```

27dec04 13:43:59 User259876 Session D698.2
  $2.21    0.692 DialUnits File155
    $2.10  10 Type(s) in Format  3
    $2.10  10 Types
$4.31 Estimated cost File155
  $4.78    0.853 DialUnits File5
    $22.75 13 Type(s) in Format  3
    $22.75 13 Types
$27.53 Estimated cost File5
  $6.04    0.617 DialUnits File73
    $2.70  1 Type(s) in Format  3
    $2.70  1 Types
$8.74 Estimated cost File73
  OneSearch, 3 files,  2.162 DialUnits FileOS
$1.50 INTERNET
$42.08 Estimated cost this search
$42.96 Estimated total session cost  2.389 DialUnits
  
```

?

**Return to logon page!**

## Refine Search

### Search Results -

Term	Documents
(10 NOT 4).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	12
(L10 NOT L4 ).PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD.	12

Database:

US Pre-Grant Publication Full-Text Database  
 US Patents Full-Text Database  
 US OCR Full-Text Database  
 EPO Abstracts Database  
 JPO Abstracts Database  
 Derwent World Patents Index  
 IBM Technical Disclosure Bulletins

Search:

L11

Refine Search

Recall Text

Clear

Interrupt

### Search History

DATE: Monday, December 27, 2004   [Printable Copy](#)   [Create Case](#)

**Set Name**   **Query**  
 side by side

**Hit Count**

**Set  
Name**  
 result set

DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI,TDBD; THES=ASSIGNEE; PLUR=YES;  
 OP=AND

<u>L11</u>	L10 not L4	12	<u>L11</u>
<u>L10</u>	L9 and (gene adj therapy)	15	<u>L10</u>
<u>L9</u>	L8 or L7	141	<u>L9</u>
<u>L8</u>	(corneal adj epithelial) adj wound	88	<u>L8</u>
<u>L7</u>	(ocular adj wound) or ((ocular adj epithelial) adj wound)	60	<u>L7</u>
<u>L6</u>	L4 and ((transforming adj growth) adj (factor adj beta))	3	<u>L6</u>
<u>L5</u>	L4 and (ocular adj wound)	3	<u>L5</u>
<u>L4</u>	((ocular adj gene) adj therapy)	17	<u>L4</u>
<u>L3</u>	L2 and ((ocular adj gene) adj therapy)	4	<u>L3</u>
<u>L2</u>	Cuthbertson-R\$.in.	48	<u>L2</u>
<u>L1</u>	Cuthbertson-Andrew-R\$.in.	1	<u>L1</u>

**PALM INTRANET**

Day : Monday  
Date: 12/27/2004  
Time: 13:17:34

## Inventor Name Search

Enter the **first few letters** of the Inventor's Last Name.  
Additionally, enter the **first few letters** of the Inventor's First name.

**Last Name****First Name**

To go back use Back button on your browser toolbar.

Back to [PALM](#) | [ASSIGNMENT](#) | [OASIS](#) | [Home page](#)